Jazz Pharmaceuticals (JAZZ) has moved back into focus after a cluster of updates on its sleep and oncology portfolios, including 21 planned Xywav data presentations at SLEEP 2026 and recently published Phase 3 Ziihera results.

Recent updates around Xywav and Ziihera, together with quarterly results that exceeded expectations, have arrived against a backdrop of strong momentum. A 90 day share price return of 28.68% and a 1 year total shareholder return of 114.68% suggest that sentiment has shifted meaningfully in Jazz Pharmaceuticals' favor.

If this kind of clinical and earnings driven move has your attention, it can be worth widening the lens to other healthcare opportunities by checking out 39 healthcare AI stocks

With Jazz shares up sharply over the past year and trading only about 6% below the average analyst target, the key question now is whether the current valuation still leaves room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 5.8% Overvalued

Against a last close of $238.57, the most followed narrative pegs Jazz Pharmaceuticals' fair value at $225.53, implying a modest premium to that model and placing more weight on detailed long term earnings assumptions than on recent share price momentum.

The analysts have a consensus price target of $225.53 for Jazz Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $188.0.

That fair value hinges on a specific path for revenue, a sharp shift in profit margins, and a future earnings multiple that differs from today. You may wish to consider which assumptions carry the most weight and how sensitive the outcome is to even small changes in those inputs.

Result: Fair Value of $225.53 (OVERVALUED)

However, patent expirations on oxybate products and execution risk around oncology launches could still disrupt earnings visibility and challenge the current fair value story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Way of Looking at Value

The analyst target suggests Jazz Pharmaceuticals is 5.8% overvalued at $238.57, but the SWS DCF model points to a very different picture, with an estimated future cash flow value of $847.26 and a 71.8% discount. When two models disagree this sharply, which one do you consider more reliable?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Jazz Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Feeling torn between the upbeat tone and the clear risk signals around Jazz Pharmaceuticals? It may be helpful to act sooner rather than later by weighing up the 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that better fit your goals, so treat this as a starting point, not the finish line.

• Target potential mispricings by reviewing companies flagged in the 49 high quality undervalued stocks that align strong fundamentals with room for market reassessment.
• Prioritise resilience by scanning the solid balance sheet and fundamentals stocks screener (46 results) to focus on companies with stronger financial footing and lower debt pressure.
• Spot early opportunities by checking the screener containing 21 high quality undiscovered gems that pair quality metrics with relatively low current market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.